SunTrust Banks Equities Analysts Raise Earnings Estimates for Affimed NV (AFMD)

Affimed NV (NASDAQ:AFMD) – Equities research analysts at SunTrust Banks raised their Q3 2018 earnings per share estimates for shares of Affimed in a research note issued on Monday, October 8th. SunTrust Banks analyst P. Lawson now forecasts that the biopharmaceutical company will post earnings per share of ($0.16) for the quarter, up from their prior forecast of ($0.17). SunTrust Banks currently has a “Buy” rating and a $5.00 target price on the stock. SunTrust Banks also issued estimates for Affimed’s Q4 2018 earnings at ($0.15) EPS, FY2018 earnings at ($0.65) EPS, FY2019 earnings at ($0.39) EPS, FY2020 earnings at ($0.39) EPS, FY2021 earnings at ($0.31) EPS and FY2022 earnings at ($0.17) EPS.

Several other equities analysts also recently issued reports on AFMD. ValuEngine downgraded shares of Affimed from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research raised shares of Affimed from a “sell” rating to a “hold” rating in a report on Tuesday, June 19th. BMO Capital Markets upped their target price on shares of Affimed from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Tuesday, August 28th. BidaskClub cut shares of Affimed from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 18th. Finally, Jefferies Financial Group raised shares of Affimed from a “hold” rating to a “buy” rating and upped their target price for the company from $1.80 to $4.00 in a report on Tuesday, August 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $4.81.

NASDAQ AFMD opened at $3.38 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.36 and a quick ratio of 5.33. Affimed has a 1 year low of $1.15 and a 1 year high of $7.35. The firm has a market capitalization of $271.40 million, a price-to-earnings ratio of -4.28 and a beta of 3.57.

Affimed (NASDAQ:AFMD) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Affimed had a negative net margin of 1,723.04% and a negative return on equity of 74.04%. The firm had revenue of $0.18 million during the quarter, compared to the consensus estimate of $0.61 million.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in Affimed in the first quarter valued at about $4,731,000. Iguana Healthcare Management LLC purchased a new position in Affimed in the first quarter valued at about $555,000. Point72 Asset Management L.P. purchased a new position in Affimed in the first quarter valued at about $463,000. Sofinnova Ventures Inc purchased a new position in Affimed in the first quarter valued at about $205,000. Finally, Canada Pension Plan Investment Board purchased a new position in Affimed in the second quarter valued at about $165,000. 40.63% of the stock is owned by hedge funds and other institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Read More: Penny Stocks, What You Need To Know

Earnings History and Estimates for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply